best stocks to buy into

Trump’s immigration policy could hurt U.S. farmers Donald Trump made clear Monday that he’s focused on immigrant visa programs — and immigration advocates and tech leaders are paying close attention.

In a short video address this week, Trump listed the issue as a priority for his first 100 days in office: He said he will “direct the Department of Labor to investigate all abuses of visa programs that undercut the American worker.”

Vivek Wadhwa, a distinguished fellow at Carnegie Mellon University’s College of Engineering, said that he was “encouraged” by what Trump didn’t mention. “What he didn’t say was that he was going to close the door to skilled immigrants,” he told CNNMoney.

best stocks to buy into: Tyson Foods Inc.(TSN)

Advisors’ Opinion:


    Cramer recalled buying Tyson Foods (TSN) for the trust in 2015 after the company acquired Hillshire Brands in 2014. The thinking was to get in early before others realized how transformative the merger would be.

  • [By Ben Levisohn]

    BMO Capital Markets analysts Kenneth Zaslow and Patrick Chen took a look at the valuations of Tyson Foods (TSN) and Pilgrim’s Pride (PPC) and decided they were afraid of heights. They explain why they cut Tyson Foods to Market Perform from Outperform…


    On Monday, Cramer said, he’ll be looking out for Tyson Foods (TSN) , Jack in the Box (JACK) and Palo Alto Networks (PANW) . Tyson is good, but out of favor, Cramer said while remaining bullish on Jack and Palo Alto.

  • [By Ben Levisohn]

    Tyson Foods (TSN) has gained 3.5% to $76.20 after beating earnings forecasts and raising its full-year guidance.

    Tesla Motors (TSLA) has fallen 1.1% to $227.50 after the auto-maker turned energy company said it would need $1.1 billion during the third quarter to fund its gigafactory and other expenses.

best stocks to buy into: Union Pacific Corporation(UNP)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Clinton 15 stock basket (DBUSCLNT): UnitedHealth Group (UNH), Humana (HUM), McKesson (MCK), Aecom (ACM), Quanta Services (PWR), ExxonMobil (XOM), Alcoa (AA), NextEra Energy (NEE), Cree (CREE), First Solar (FSLR), Facebook (FB), Netflix (NFLX), Prudential Financial (PRU), Citigroup (C), Union Pacific (UNP).

  • [By Manikandan Raman]

    Expecting a rebound in fundamentals, Bernstein maintains its Outperform rating on Union Pacific Corporation (NYSE: UNP) despite a third-quarter EPS miss and cautious commentary on pricing.

best stocks to buy into: Insys Therapeutics, Inc.(INSY)

Advisors’ Opinion:

  • [By James E. Brumley]

    When most most investors thik of medical marijuana — actual cannabinoid drugs rather than just an edible that names marijuana plant as an ingredient — companies like GW Pharmaceuticals PLC (NASDAQ:GWPH) and Insys Therapeutics Inc (NASDAQ:INSY) come to mind. And, that’s largely as it should be. Insys Therapeutics’ dronabinol oral solution, Syndros(tm), is the FDA’s first-ever approved orally-administered liquid formula of the pharmaceutical cannabinoid dronabinol, which is a pharmaceutical version of tetrahydrocannabinol (“THC”). (Syndros treatment for anorexia-driven weight loss in patients with AIDS.) And, GW Pharmaceuticals’ cannabinoid-based Sativex is already approved in several countries as a means of controlling muscle spasticity for multiple sclerosis patients. It’s also being tried as a means of pain-control in cancer patients.

    Both companies’ portfolios and pipelines are promising, as are cannabinoid in general. An up-and-coming company called called Vitality Biopharma Inc (OTCMKTS:VBIO), however, may well take the science of cannabis to a whole new level.

    Vitality Biopharma’s work so far has been focused on the use of cannabidiol as a means of creating better drugs.

    Cannabidiol is a non-psychotropic derivative of cannabis, which has shown therapeutic effects for serious neurological conditions including rare seizure disorders, and for alleviating symptoms of multiple sclerosis. Vitality Biopharma’s prodrugs (drug that are converted into their effective form after being processed in the body) could exert the same beneficial therapeutic effects. Howver, they could do so better than most rival cannabinoid drugs do.

    How so? Part of the overarching answer is, Vitality Biopharma’s work has been in turning cannabidiol into a prodrug. This allows for targeted delivery within the body, even to the brain. Perhaps the biggest edge cannabidiol-based drugs have over cannabinoids, though, is that they’re non-psychotr

  • [By Matthew Briar]

    When many investors think of medical marijuana — real cannabinoid drugs as opposed to a food or drink with some sort of marijuana plant listed as an ingredient — companies like GW Pharmaceuticals PLC (NASDAQ:GWPH) and Insys Therapeutics Inc (NASDAQ:INSY) come to mind. That’s not unreasonable. Insys Therapeutics’ dronabinol oral solution, Syndros(tm), is the first FDA- approved orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol… a pharmaceutical version of tetrahydrocannabinol (“THC”). Syndros treats anorexia-driven weight loss for AIDS patients. n the meantime, GW Pharmaceuticals’ cannabinoid-based Sativex has already been approved in several countries as a way of reducing muscle spasticity for multiple sclerosis patients. It’s also being tried as a pain-control drug for cancer patients, demonstrating not just the efficacy of cannabinoids, but the diversity of what the can do.

    Each company’s portfolio and pipeline are promising, as are cannabinoids in general. A yound and hungry outfit called Vitality Biopharma Inc (OTCMKTS:VBIO), though, may take the science of cannabinoid to the next proverbial level.

    Vitality Biopharma’s work so far has aimed to make cannabidiol the next generation of cannabinoid drugs.

    Cannabidiol is a non-psychotropic (meaning it doesn’t get you “high) form of cannabis, and has demonstrated therapeutic effects for major neurological conditions like rare seizure disorders, and also as a way of treating symptoms of multiple sclerosis. Vitality Biopharma’s prodrugs [drugs that are converted into their effective form after being processed in the body] could exert the same therapeutic effects. But, Vitality’s drugs could do this better than most cannabinoids currently do.

    How so? Broadly speaking, and as was noted, Vitality Biopharma’s work to-date has focused on turning cannabidiol into a prodrug, or a drug that doesn’t become its final, active form until it’s

  • [By Motif Investing]

    Cannabis consulting business Medicine Man Technologies Inc (OTC: MDCL) is one such company that started trading over the counter earlier this year. Terra Tech Corp (OTC: TRTC), Insys Therapeutics Inc (NASDAQ: INSY) and GW Pharmaceuticals plc (NASDAQ: GWPH) are two other companies that investors can access.

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell by 0.20 percent. Meanwhile, top losers in the sector included Horizon Pharma PLC (NASDAQ: HZNP), down 20 percent, and Insys Therapeutics Inc (NASDAQ: INSY), down 17 percent.

best stocks to buy into: Fiat Chrysler Automobiles N.V.(FCAU)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    Across the industry, days to turn averaged 72. The number was never below 60 in any month of 2016. It has gotten larger since the year has passed, up from 62 in January. Bycontrast with Subaru, the number for Fiat Chrysler Automobile N.V.’s (NYSE: FCAU) Ram pickup division was 128 in October. Dodge and Fiat were both over 100.

  • [By Paul Ausick]

    Among the Detroit Three the outlook is decidedly mixed. According to researchers at Kelley Blue Book (KBB), General Motors Co. (NYSE: GM) is forecast to sell 249,000 units, up 8.6% compared with November of 2015. GM’s U.S. market share is expected to reach 18.2%, up 0.7 percentage point year over year. Ford Motor Co. (NYSE: F) is touted to post a sales gain of just 0.1% with 189,000 units for a market share of 13.6%, down 0.6 point year over year. Fiat Chrysler Automobiles NV (NYSE: FCAU) is forecast to see unit sales drop 4.5% year over year to 168,000 and a market share of 12.3%, down 1.1 percentage points.

  • [By Paul Ausick]

    While Ford was converting its production lines to accommodate its all-new 2015 aluminum-bodied F-150, General Motors Co. (NYSE: GM) and Fiat Chrysler N.V. (NYSE: FCAU) upped their market shares and attracted a lot of buyers unwilling to wait for Ford’s new pickups.

best stocks to buy into: Hatteras Financial Corp(HTS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Hatteras Financial (HTS) has jumped 9.4% to $15.60 after agreeing to be purchased byAnnaly Capital Management (NLY) for $1.5 billion.Annaly Capital Management has dropped 1.1% to $$10.30.

Leave a Reply

Your email address will not be published. Required fields are marked *